Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Topical roflumilast provided significant improvements in severity and burden of itch in Phase 3 plaque psoriasis studies, as well as Phase 2 studies in seborrheic dermatitis and scalp and body...
-
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
-
WESTLAKE VILLAGE, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
-
WESTLAKE VILLAGE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
-
WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to...
-
Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitorScalp and body psoriasis affects more than 8 million patients in the U.S. WESTLAKE VILLAGE, Calif., Aug. 25, 2021 (GLOBE...
-
WESTLAKE VILLAGE, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to...
-
Anticipates submission of a New Drug Application (NDA) for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of...
-
Eric McIntyre joins as Head of Investor RelationsAmanda Sheldon joins as Head of Corporate Communications WESTLAKE VILLAGE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics,...
-
The majority of patients with psoriasis have mild or moderate levels of diseaseThe new method, PASI-high discrimination (PASI-HD), is designed for use in clinical trials evaluating novel topical...